Call to standardize Sabin IPV

Medical experts and representatives of pharmaceutical organizations called for standardization of Sabin's inactivated poliomyelitis vaccine on Wednesday

. A global workshop organized by PATH, a non-profit organization based in Seattle, is underway. plan that would eventually lead to the standardization of the inactivated Sabin vaccine. The Sabin vaccine is one of two types available against polio. Sabin's VPI, unlike the original IPV, includes inactivated poliovirus types that are made from the weakened polio virus used in oral polio vaccine (OPV). The original VPI developed includes inactivated wild-type viruses that present a risk of manipulation and containment. According to Kutub Mahmood, scientific director of the vaccine development program at PATH, Afghanistan and Pakistan are the last two countries where polio infections continue to be reported. Explaining the need for a standardization of the IPV vaccine, Mahmood said that at present, different manufacturers are using varying concentrations of viral components.